Vertex is running a phase 2 trial of inaxaplin in APOL1-mediated kidney diseases, including some forms of FSGS. The phase 3 ...

In a multicenter, phase 2 trial across 31 centers in 10 countries, apecotrep (BI 764198) reduced proteinuria by 40% over 12 ...

Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental ...

Boehringer Ingelheim has reported encouraging Phase II trial results for apecotrep (BI 764198), a potential first-in-class oral TRPC6 inhibitor being developed for primary focal segmental ...

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with prima ...